Susquehanna International Group
ALXO icon

Susquehanna International Group’s ALX Oncology ALXO Stock Holding History

Susquehanna International Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66M Buy
1,328,907
+1,177,880
+780% +$2.24M ﹤0.01% 5525
2025
Q4 		$171K Buy
151,027
+37,964
+34% +$57.5K ﹤0.01% 11044
2025
Q3 		$207K Sell
113,063
-50,750
-31% -$44K ﹤0.01% 10923
2025
Q2 		$68K Buy
163,813
+42,103
+35% +$21.2K ﹤0.01% 12002
2025
Q1 		$75.8K Sell
121,710
-29,910
-20% -$35.9K ﹤0.01% 11696
2024
Q4 		$253K Buy
151,620
+121,272
+400% +$186K ﹤0.01% 10187
2024
Q3 		$55.2K Buy
30,348
+5,787
+24% +$21.5K ﹤0.01% 11342
2024
Q2 		$148K Buy
24,561
+859
+4% +$10.6K ﹤0.01% 10706
2024
Q1 		$264K Sell
23,702
-15,813
-40% -$222K ﹤0.01% 9997
2023
Q4 		$588K Sell
39,515
-12,569
-24% -$119K ﹤0.01% 8259
2023
Q3 		$250K Buy
52,084
+22,675
+77% +$123K ﹤0.01% 9744
2023
Q2 		$221K Buy
29,409
+17,054
+138% +$112K ﹤0.01% 10076
2023
Q1 		$55.8K Buy
+12,355
New +$93.6K ﹤0.01% 11649
2022
Q3 		– Sell
-25,193
Closed -$294K – 13097
2022
Q2 		$204K Sell
25,193
-30,219
-55% -$329K ﹤0.01% 10580
2022
Q1 		$936K Buy
55,412
+2,542
+5% +$43.4K ﹤0.01% 7298
2021
Q4 		$1.14M Buy
52,870
+37,018
+234% +$1.6M ﹤0.01% 6952
2021
Q3 		$1.17M Sell
15,852
-6,309
-28% -$420K ﹤0.01% 7152
2021
Q2 		$1.21M Sell
22,161
-13,089
-37% -$783K ﹤0.01% 7217
2021
Q1 		$2.6M Buy
35,250
+30,068
+580% +$2.37M ﹤0.01% 5295
2020
Q4 		$447K Buy
+5,182
New +$312K ﹤0.01% 8523

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Susquehanna International Group's ALXO Position: Q1 2026 in Review

Susquehanna International Group increased its ALX Oncology (ALXO) stake by 780% in Q1 2026, buying an estimated $2.24M and bringing the position to 1,328,907 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #5525.

Susquehanna International Group first reported a position in ALXO in Q4 2020 and has held it in 20 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Susquehanna International Group held 1,328,907 shares of ALX Oncology worth $2.66M as of Q1 2026.
  • Susquehanna International Group bought 1,177,880 ALX Oncology shares in Q1 2026, an estimated $2.24M.
  • ALX Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5525 holding.
  • Susquehanna International Group first reported a position in ALX Oncology in Q4 2020 and has held it in 20 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.